<DOC>
	<DOCNO>NCT01773018</DOCNO>
	<brief_summary>Volitinib ( HMPL-504 ) novel , highly potent selective small molecule inhibitor c-Met kinase . In preclinical study , demonstrate strong vitro vivo activity c-Met kinase downstream signal target inhibit tumor cell growth . This first-in-human study conduct assess maximum tolerate dose ( MTD ) dose-limiting toxicity ( DLT ) , evaluate pharmacokinetics , safety preliminary anti-tumor activity HMPL-504 single dos multiple dos .</brief_summary>
	<brief_title>Phase I Study Volitinib ( HMPL-504 ) Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>This Phase I , first-in-human , open-label , dose-escalation study Volitinib ( HMPL-504 ) administer orally every day ( QD ) patient locally advance metastatic solid tumors.There two stage study : dose-escalation stage dose-expansion stage . The dose-escalation stage design evaluate safety , tolerability , pharmacokinetics single dose repeat dose HMPL-504 give every day ( QD ) . An alternative dosing schedule twice every day ( BID ) may investigate pharmacokinetic study indicate faster anticipated clearance HMPL-504 . All patient carefully follow adverse event study treatment 30 day last dose study drug . Subjects study permit continue therapy safety monitoring bimonthly assessment progression , product well tolerated subject stable disease well .</detailed_description>
	<criteria>Signed Informed Consent Form Age≥18 year Histologically cytologically document , incurable , locally advanced , metastatic solid malignancy progress , fail respond , least one prior systemic therapy Evaluable measurable disease per Response Evaluation Criteria Solid Tumors ( RECIST ) Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 Male female patient childproducing potential must agree use double barrier contraception , condom , sponge , foam , jelly , diaphragm intrauterine device ( IUD ) , contraceptive ( oral parenteral ) , Implanon , injectables avoidance pregnancy measure study 90 day last day treatment In dose expansion stage , patient 's informed consent provide fresh biopsy tumor sample baseline day 7 obtain . Patients gastric cancer , NSCLC , colorectal cancer , breast cancer hepatocellular carcinoma ( HCC ) prefer enrol dose expansion cohort . • Inadequate hematologic organ function , define follow ( hematologic parameter must assess ≥14 day prior treatment , ) : Absolute neutrophil count ＜1500 cells/L Hemoglobin ＜9 g/dL Total bilirubin ＞1.5 × upper limit normal （ULN） follow exception : Patients know Gilbert disease serum bilirubin level ≤3× upper limit normal（ULN） normal AST/ALT may enrol . Aspartate aminotransferase （AST） and/or Alanine transaminase（ALT） ＞2.5 × upper limit normal（ULN） follow exception : Patients document liver metastasis may AST and/or ALT level ≤5 ×the upper limit normal（ULN） . Serum creatinine ＞1.5 × upper limit normal ( ULN ) follow exception : A creatinine clearance ≥50 mL/min base document 24hour urine collection . International normalized ratio ( INR ) ＞1.5× ULN activate partial thromboplastin time ( aPTT ) ＞1.5×the ULN The INR apply patient receive therapeutic anticoagulation . • Any anticancer therapy , include chemotherapy , hormonal therapy , biologic therapy , radiotherapy , herbal therapy within 4 week prior initiation study treatment follow exception : Hormonal therapy gonadotropinreleasing hormone ( GnRH ) agonists prostate cancer Hormonereplacement therapy oral contraceptive Palliative radiation bone metastases ＞ 2 week prior Day 1 Herbal therapy ＞1 week prior Day 1 Adverse event prior anticancer therapy resolve Grade ≤ 1 , except alopecia Clinical significant active infection Known clinically significant history liver disease , include viral hepatitis , current alcohol abuse , cirrhosis Known human immunodeficiency virus infection Pregnant ( positive pregnancy test ) lactate woman New York Heart Association ( NYHA ) Class II great congestive heart failure History myocardial infarction unstable angina within 6 month prior Day 1 History stroke transient ischemic attack within 6 month prior Day 1 Active untreated brain metastasis Inability take oral medication , prior surgical procedure affect absorption , active peptic ulcer disease Inability comply study followup procedure Any disease , metabolic dysfunction , physical examination finding , clinical laboratory finding , investigator 's opinion , give reasonable suspicion disease condition contraindicate use investigational drug may affect interpretation result render patient high risk treatment complication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>